Cross‐over study in hyperammonemia patients for efficacy, safety, and acceptability of a new lactulose preparation (SK‐1202) compared to approved drug. Issue 13 (9th August 2018)

• Record Type: Journal Article
• Authors: Yoshiji, Hitoshi; Karino, Yoshiyasu; Suzuki, Yoshiyuki; Suzuki, Fumitaka; Uejima, Masakazu; Aikata, Hiroshi; Chayama, Kazuaki; Iwai, Hisakazu; Suzuki, Eiji; Kumada, Hiromitsu
• Is Part Of: Hepatology research. Volume 48:Issue 13(2018)
• Page Start: 1178
• Page End: 1183
• Publication Date: 2018-08-09
• Subjects: hyperammonemia -- lactulose -- liver cirrhosis -- new preparation -- SK‐1202 -- taste; Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.13228
• Languages: English
• ISSNs: 1386-6346

Abstract

Abstract : Aim: A novel jelly lactulose preparation (SK‐1202) has been developed to improve compliance and reduce the elevation of blood glucose levels in diabetic patients. To compare the equivalence in the efficacy and safety of SK‐1202 and an approved commercially available syrup preparation, we undertook a randomized multicenter cross‐over study in hyperammonemia patients with liver cirrhosis who were taking lactulose. Methods: Forty‐four patients were enrolled and took each preparation for 2 weeks. Efficacy was evaluated using the Number Connection Test, blood ammonia concentration, coma grade, and the flapping tremor grade. Safety was evaluated by the number of adverse events observed, vital signs, and laboratory tests. We also examined the acceptability of each preparation using questionnaires evaluating sweetness, aftertaste, ease of use, and preference of the preparations. Results: There were no differences in efficacy or safety between SK‐1202 and the approved syrup preparation. With regard to the acceptability evaluation, given over 80% of the participants chose the SK‐1202 preparation, it appears to be preferred by patients. Conclusions: It is expected that SK‐1202 could represent a useful agent for patients with hepatic encephalopathy.